The cytokine receptor common gamma chain (␥c) plays a pivotal role in multiple interleukin signaling, and ␥c The cytokine receptor common gamma chain (␥c) is shared among the receptors for interleukin
and plays a pivotal role in transmitting these cytokine signals. 1, 2 Many of these signals are indispensable for lymphoid development and activation. Accordingly, mutations in the X-linked ␥c gene result in severe developmental failure of lymphoid tissues and immune function, a disorder known as X-linked SCID (X-SCID). 3, 4 T cells and natural killer (NK) cells are profoundly diminished in those afflicted with this disorder, and B cells are present but nonfunctional. The affected patients suffer from recurrent and severe infections, usually leading to death in infancy or early childhood.
Until recently, the only cure for X-SCID has been allogeneic BMT. This procedure usually reconstitutes T cells and NK cells, but frequently humoral immunity is only partially reconstituted, and many patients depend upon regular immunoglobulin supplementation. 5 The reason for this B cell refractoriness is still unknown; pre-existing B cells may prevent the donor cells from engrafting under the non-ablative BMT protocols currently used for X-SCID.
Recently, Cavazzana-Calvo et al 6 showed that hematopoietic stem cell gene transfer was effective in treating X-SCID. Autologous BM CD34
+ cells were retrovirally transduced and reinfused into patients, and a successful T and NK cell reconstitution was observed in most cases. Whether B cell function can be fully reconstituted is to be clarified in a long-term study. The apparent success of X-SCID stem cell gene transfer makes a sharp contrast to the limited success in previous clinical trials targeting hematopoietic stem cells. Although recent advances in gene transfer such as newly introduced early-acting cytokines (TPO and Flt3 ligand) and the recombinant fibronectin fragment (CH296) may have augmented gene transfer efficacy, 7 it is unlikely that the Moloney-based retrovirus vector has achieved a dramatic increase in transduction efficiency into human hematopoietic stem cells.
One possibility that may account for their success is the pathogenesis of X-SCID and the function of ␥c. Once hematopoietic stem cells or lymphoid progenitors are transduced with a functional ␥c gene, these cells can exclusively utilize the growth signals via IL-7 and other cytokines. That is, the therapeutic gene itself confers a tremendous growth advantage on the transduced cells, a situation rarely encountered in stem cell gene therapy for other diseases. To examine the strength of the selective advantage that lymphocytes with normal ␥c expression have over ␥c-deficient cells, we injected limited numbers of wild-type (WT) BM cells into non-ablated WT and X-SCID mice, and monitored the engraftment of the donor cells.
Materials and methods

Animals
Inbred C57BL/6-Ly5.2 mice were purchased from Clea Japan (Tokyo, Japan). The congenic C57BL/6-Ly5.1 mice are maintained in the animal facility of Jichi Medical School (Tochigi, Japan). A murine X-SCID model was created by targeted disruption of the X-linked ␥c gene. 8 The X-SCID mice were back-crossed to a C57BL/6-Ly5.2 background and an inbred colony was established. Meanwhile, congenic X-SCID mice were established by crossing with C57BL/6-Ly5.1 mice. The animals were maintained in a specific pathogen-free environment in the institutional animal facility and treated following institutional codes for animal rights.
BMT BM cells were obtained from 6-week-old WT C57BL/6-Ly5.2 mice by flushing the femora with ␣-Minimum Essential Medium (Life Technologies, Grand Island, NY, USA), and the low-density mononuclear cells were obtained by density centrifugation on Lympholyte-M (Cedarlane, Hornby, Ontario, Canada). Either 10 5 , 10 6 or 10 7 cells were injected into WT C57Bl/6-Ly5.1 and X-SCID C57BL/6-Ly5.1 recipients (8-to 10-week-old) via the tail vein without prior myeloablation.
Blood count and flow cytometry
Mouse peripheral blood was obtained by tail clipping and a complete blood count was made with a PC-608 particle counter (Erma, Tokyo, Japan). Prior to flow cytometry, RBC were lysed with ACK buffer (150 mm NH 4 Cl, 12 mm KHCO 3 , and 0.125 mm EDTA) for 15 min on ice. WBC were stained with MoAbs specific for Ly5.1, Ly5.2, Gr1, Mac1, CD4, CD8, B220, IgM, TCR␤ and NK1.1 (Pharmingen, San Diego, CA, USA), and analyzed with a FACScan (Becton Dickinson, San Jose, CA, USA).
Results
Lymphocyte reconstitution
The X-SCID mouse model was created by a partial replacement of the ␥c gene with a neo cassette, resulting in a deletion of the ␥c cytoplasmic domain required for signal transduction. 8 Similar mutations are found in a subset of X-SCID patients, whose phenotypes are indistinguishable from those with null mutations. 4 In mice, hemizygous males and homozygous females have a hypoplastic thymus and other lymphoid tissues, and are markedly lymphopenic. In addition to a profound reduction or absence of T cells and NK cells as observed in human X-SCID patients, the mice show significant B lymphopenia. B cell reduction is commonly observed in murine X-SCID models created with different targeting constructs, [8] [9] [10] suggesting that mouse B cells are more profoundly dependent on ␥c-mediated signals than their human counterparts. In the older X-SCID mice used in this study, a relative accumulation of CD4 + T cells was observed, but the reason for this aberrant lymphopoiesis is yet to be determined. 8 As described, the X-SCID recipients were severely lymphopenic before BMT. 8 Whereas lymphocytes accounted for 80-85% of total WBC in WT, lymphoid cells accounted for only 5-15% in X-SCID, and the absolute lymphocyte count in X-SCID was 150-450/l (1-3% of WT control; Table 1 ). As for the myeloid lineage, a relative granulocytosis and monocytosis was observed in X-SCID mice, but the absolute number of myeloid cells (2000-4000/l) did not show a significant difference from WT animals.
A single infusion of 10 6 or 10 7 WT BM cells led to a marked increase of lymphocytes in the X-SCID recipients. One month following BMT, mice having received 10 6 or 10 7 cells showed a significant increase (P = 0.023 and P = 0.0003 by paired t-test) of total lymphocytes, and the lymphocyte counts steadily increased thereafter. Five months after BMT, lymphocyte numbers in the X-SCID recipients were 35 Ϯ 11% and 73 Ϯ 8% of the WT control, with infusion of 10 6 cells and 10 7 cells, respectively (Table  1 and Figure 1a) . The lymphocyte increase in X-SCID mice infused with 10 5 cells was less prominent, and was statistically significant only at 3 months (P = 0.01) and 5 months (P = 0.046) following BMT (Figure 1a) . During the observation period, the lymphocyte count in WT recipients was unchanged.
Lymphocyte reconstitution was observed in all the subsets examined (CD4 + T, CD8 + T, B and NK cells). Figure  1 shows the absolute counts of lymphocyte subsets during the observation period, and Table 1 summarizes the endpoint results at 5 months post BMT. At this point, relative lymphoid reconstitution in the X-SCID mice infused with 10 6 cells was 28 Ϯ 12%, 68 Ϯ 23%, 25 Ϯ 10% and 16 Ϯ 6% for CD4 + T, CD8 + T, B and NK cells. At the same time, the X-SCID mice that received 10 7 cells had 52 Ϯ 9%, 111 Ϯ 27%, 87 Ϯ 11% and 53 Ϯ 16% of the CD4
+ T, B and NK cells of the WT controls. That is, CD8
+ T cells and B cells were within the normal range and CD4 + T cells and NK cells were half-normal, after 10 7 cells were given to the X-SCID mice.
Overall WBC chimerism
Successful lymphocyte reconstitution in the X-SCID recipients was concordant with donor cell engraftment. Donorderived Ly5.2 cells rapidly repopulated in the X-SCID mice, and as early as 1 month post BMT, the overall WBC chimerism was 9. 
WT = wild-type; X-SCID = X-linked SCID.
respectively ( Figure 2 ). As is described in detail below, the donor cell chimerism was mostly attributable to Ly5.2 + lymphocytes, since the donor-derived myeloid cells engrafted poorly (see Lineage chimerism and Figure 3 ). With such a lineage-biased engraftment, the overall chimerism can be calculated approximately as a function of the lymphocyte increase in the X-SCID transplants. For example, as seen in Figure 1a , infusion of 10 7 WT BM cells resulted in an increase of the average lymphocyte count from 200/l (0 month) to 2000/l (1 month). Assuming that the average myeloid cell number was unchanged (3000/l), the overall WBC chimerism would be (2000 Ϫ 200)/(2000 + 3000) = 0.36. Similarly, these animals had about 10 000/l lymphocytes 5 months post BMT, and the chimerism would be (10 000 Ϫ 200)/(10 000 + 3000) = 0.75, which is quite close to the observed value. The calculation would be even more accurate if one considers myeloid cell numbers. For unknown reason(s), myeloid cells in the X-SCID transplanted with 10 7 cells decreased slightly at 3 months and rebounded later (the difference was not significant; data not shown). In the meantime, their lymphocytes continued to increase (Figure 1a) , making overall chimerism almost unchanged.
In contrast to X-SCID, the donor cells did not engraft in WT recipients. Ly5.2 + WBC never reached 1% in the WT Ly5.1 mice, even after 10 7 cells were transplanted. Assuming that the total number of BM cells in a mouse is 2 ϫ 10 8 , 10
7 accounts for only 5%. Considering the homing efficiency following tail vein i.v., the actual number of engrafting cells would be even fewer. Therefore, without preconditioning, graft failure in recipients with normal hematopoiesis is a likely consequence. On the other hand, the observed high donor chimerism in X-SCID was quite remarkable, indicating that the WT cells were extremely competitive in the X-SCID recipients.
Lineage chimerism
Although WT cells engrafted in the unconditioned X-SCID recipients, not all the hematopoietic lineages repopulated equally well. In a series of flow cytometric analyses, donor cell chimerism was evaluated by counting Ly5. Figure 3 suggested that a growth advantage among ␥c + cells in X-SCID was greatly biased toward lymphocytes. Because lymphoid cells depend solely on ␥c-mediated signals, the advantage of ␥c + cells over X-SCID cells should be overwhelming. Myeloid cells primarily depend on other cytokine signals, and pre-existing granulocytes and monocytes can prevent the same lineage cells from engrafting after unconditioned BMT. It is of note, however, that the engraftment of myeloid cells was better in the X-SCID recipients than in the WT animals. This may suggest that the Ly5-congenic cells were somewhat immunogenic in the uncompromised hosts, and that the reason for the Ly5.2 lymphocyte proliferation in the Ly5.1 X-SCID was twofold (see Discussion).
Discussion
In the present study, we showed that WT (␥c + ) lymphocytes had a selective advantage in X-SCID recipients after BMT without conditioning. For as long as we have tested, the extent of donor cell repopulation has been dose-dependent, and infusion of limited numbers (10 6 or 10 7 ) of WT BM cells resulted in a significant repopulation of all the lymphoid subsets examined such as CD4 + T, CD8 + T, B and NK cells. We assumed that WT cells corresponding to only 5% of total BM cells could reconstitute the hosts' lymphoid systems to a half-to near-normal levels. It is of interest to compare the engrafting potential of WT cells in other types of immunodeficiency disorders. Rohrer mice. They transplanted limited numbers of WT BM cells together with excess xid cells into lethally irradiated xid mice. An approximately 10-fold enrichment of WT B cells over xid cells was observed, and the humoral immunity was reconstituted. In our study, WT cells showed an apparently stronger selective advantage in X-SCID mice than in xid mice. Presumably, the dependency of the lymphoid lineage on the ␥c-mediated signal is much greater than that of B cells on the Btk-mediated signals. Such an enormous proliferative potential of the ␥c + lymphoid progenitor was suggested in an atypical case of X-SCID. Reportedly, a reversal event in the mutated ␥c gene resulted in a functional lymphoid precursor generating at least 1000 T cell clones, and the disease phenotype being significantly ameliorated. 12, 13 Besides the engrafting potential of the donor cells, one should consider the immunogenicity of the donor cells and the host's immune status in BMT experiments. Although the chimerism was low, we observed that WT BM-derived granulocytes and monocytes engrafted better in X-SCID recipients than in WT animals ( Figure 3 ). Since myeloid cells primarily depend on growth and differentiation signals other than ␥c-mediated ones, expression of the functional ␥c alone may not account for the low-level, but substantial The results of this report provide strong support for the hypothesis that the selective growth advantage of lymphoid precursors with a functional ␥c played a critical role in the gene therapy trial for X-SCID. The growth advantage seems to be direct and much stronger than the benefit from the adenosine deaminase (ADA) gene transfer. The functional ADA gene can confer a survival advantage on lymphoid precursors, so that the transduced lymphocytes accumulated in the ADA-deficient SCID patients. 15 However, the advantage seems to be insufficient to expand genecorrected cells for clearing metabolic toxicity, so that only minimal immune reconstitution was achieved in the stem cell-targeted ADA gene transfer trials. Hence, there is a need to maximize, or boost, the growth advantage of the transduced cells for successful gene therapy of diseases other than X-SCID and perhaps Jak3-deficient SCID.
